FRACTYL HEALTH INC (GUTS) Stock Price, Quote, News and Overview
NASDAQ:GUTS - Nasdaq - US35168W1036 - Common Stock - Currency: USD
GUTS Quote, Performance and Key Statistics
FRACTYL HEALTH INC
NASDAQ:GUTS (2/7/2025, 6:47:07 PM)
After market: 1.57 +0.06 (+3.97%)1.51
-0.1 (-6.21%)
The current stock price of GUTS is 1.51 USD. In the past month the price decreased by -20.53%. In the past year, price decreased by -84.95%.
GUTS Latest News and Analysis
What's going on in today's pre-market session
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025
Prioritizing Revita’s clinical development on weight maintenance post-GLP-1 withdrawal in response to significant patient and physician demand in ongoing...
GUTS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 27.64 | 223.87B | ||
| ISRG | INTUITIVE SURGICAL INC | 79.53 | 207.65B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.93 | 155.12B | ||
| SYK | STRYKER CORP | 32.11 | 149.21B | ||
| MDT | MEDTRONIC PLC | 17.14 | 115.42B | ||
| BDX | BECTON DICKINSON AND CO | 17.47 | 66.66B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.35 | 41.49B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.77 | 40.04B | ||
| IDXX | IDEXX LABORATORIES INC | 40.87 | 37.65B | ||
| RMD | RESMED INC | 26.8 | 34.78B | ||
| DXCM | DEXCOM INC | 51.81 | 34.40B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 20.51 | 25.64B |
Related stock screener links
About GUTS
Company Profile
Fractyl Health, Inc. is a metabolic therapeutics company. The company is headquartered in Burlington, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2024-02-02. The firm is focused on approaches to the treatment of metabolic diseases, including type 2 diabetes (T2D) and obesity. The Revita DMR System (Revita), the Company’s lead product candidate, is an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The Revita system is designed to enable durable and repeatable metabolic improvement via hydrothermal ablation of the dysfunctional duodenal mucosa to address duodenal pathology and consequent metabolic disease progression directly. The firm is involved in enrolling is pivotal Revitalize-1 study in patients with inadequately controlled T2D. The company is also developing Rejuva, a locally administered, adeno-associated virus (AAV), delivered pancreatic gene therapy (PGTx), platform. Rejuva is designed to enable long-term remission of T2D and obesity.
Company Info
FRACTYL HEALTH INC
3 Van De Graaff Drive, Suite 200
Burlington MASSACHUSETTS US
Employees: 102
Company Website: https://www.fractyl.com/
Phone: 17819028800
GUTS FAQ
What is the stock price of GUTS?
The current stock price of GUTS is 1.51 USD.
What is the symbol for FRACTYL HEALTH INC stock?
The exchange symbol of FRACTYL HEALTH INC is GUTS and it is listed on the Nasdaq exchange.
On which exchange is GUTS stock listed?
GUTS stock is listed on the Nasdaq exchange.
Is GUTS a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for GUTS, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of GUTS.
Does GUTS stock pay dividends?
GUTS does not pay a dividend.
What is the Price/Earnings (PE) ratio of GUTS?
GUTS does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.43).
What is the Short Interest ratio of GUTS stock?
The outstanding short interest for GUTS is 5.96% of its float.
GUTS Technical Analysis
GUTS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GUTS. Both the profitability and financial health of GUTS have multiple concerns.
GUTS Financial Highlights
Over the last trailing twelve months GUTS reported a non-GAAP Earnings per Share(EPS) of -1.43. The EPS decreased by -46.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.34% | ||
| ROE | -137.06% | ||
| Debt/Equity | 0.6 |
GUTS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to GUTS. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 95.71% and a revenue growth -55.75% for GUTS